Patient Perspectives on Generalized Myasthenia Gravis: Highlighting the Need for Emerging FcRn Antagonist Treatment

Patient Perspectives on Generalized Myasthenia Gravis: Highlighting the Need for Emerging FcRn Antagonist Treatment

Med-IQ Select
Continue to Course
Online Course | Specialties: Neurology
Released: 2/28/2022
Expires: 2/27/2023
Max Credits: 1.0
Continue to Course Read Abstract

Ali A. Habib, MD
Associate Professor, Department of Neurology
Director, EMG Laboratory
University of California, Irvine
Irvine, CA

Niraja S. Suresh, MD
Assistant Professor, Department of Neurology
Associate Director, EMG Laboratory
University of South Florida Morsani College of Medicine
Tampa, FL

Activity Planners
Amy Burdette, PhD
Manager, Educational Strategy & Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Recognize the effects of the disease burden and treatment on patients living with gMG
  • Identify the benefits and limitations of available treatments for gMG
  • Integrate the latest clinical data regarding the efficacy and safety of FcRn antagonists into practice as these agents become available for the treatment of gMG

Target Audience
This activity is intended for advanced care practitioners in neurology (eg, neuromuscular, neuroimmunology, neuro-ophthalmology, general neurology) and pharmacists.

Statement of Need
Myasthenia gravis (MG) often has a heterogeneous presentation, which necessitates the individualization of treatment to best manage each patient’s symptoms and disease activity. Available treatment options for MG either address symptoms or modulate and suppress the immune system. Immunosuppressive therapy needs to be initiated early in the disease course for patients with generalized MG (gMG), as symptomatic therapy does not provide adequate disease control. Although available treatments may effectively control disease activity for some individuals with gMG, they are associated with long-term adverse effects and delayed efficacy, as well as intolerance in some patients, underscoring the need for new therapies. A greater understanding of the underlying pathophysiology of MG has led to the identification of the neonatal Fc receptor (FcRn) as a new potential treatment target, with several FcRn antagonists now in clinical trials. To best address the treatment needs of their patients, clinicians need to be familiar with these and other emerging therapies for gMG, their efficacy and safety data, and their potential place in the MG treatment landscape.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Med-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hour (0.10 CEUs) of credit for pharmacists. ACPE #0476-0000-22-001-H01-P. This knowledge-based activity is designed for all pharmacists.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium and Method of Participation
This is a 1.0-credit CME/CE activity. To receive credit, read the introductory CME/CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly. Pharmacists will have credits uploaded directly to NABP.

Initial Release Date: February 28, 2022
Expiration Date: February 27, 2023
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Ali A. Habib, MD
Consulting fees/advisory boards: argenx, UCB, Inc.
Contracted research: Alexion Pharmaceuticals, Inc., argenx, Immunovant, Inc., Momenta Pharmaceuticals, Pfizer, Inc., UCB, Inc., Viela Bio

Niraja S. Suresh, MD
Consulting fees/advisory boards: argenx, Alexion Pharmaceuticals, Inc., Alnylam
Fees received for promotional/non-CME activities: Pfizer, Inc., Takeda Pharmaceuticals North America, Inc.

The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Complimentary CME/CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from agrenx.



Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit are available at the "Continue" button below.

  • MG is a rare, neuromuscular, autoimmune disorder affecting approximately 700,000 people worldwide
  • The manifestations of MG negatively affect individuals’ quality of life and daily functioning, including their ability to eat, drive, work, and care for family members
  • The pathophysiology of MG is still not completely elucidated, but the production of IgG autoantibodies to the acetylcholine receptor plays a central role in causing the clinical manifestations of fatigable and persistent muscle weakness
  • Due to MG’s heterogeneous presentation, there is no internationally recognized standard of care, and treatment decisions must be individualized to best address patients’ needs
  • Targeting the FcRn has emerged as a new treatment approach for MG
  • Several FcRn inhibitors are producing promising results in clinical trials and may be available in the near future for select patients with MG

View reference list.

Click “Continue” to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the chapters in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.